Annual Drug Patent Expirations for EVOTAZ
Evotaz is a drug marketed by Bristol-myers Squibb and is included in one NDA. It is available from one supplier. There are two patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for EVOTAZ.
This drug has two hundred and thirty-seven patent family members in thirty-nine countries.
The generic ingredient in EVOTAZ is atazanavir sulfate; cobicistat. One supplier is listed for this compound. Additional details are available on the atazanavir sulfate; cobicistat profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
